ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Terrence O. Moore sold 157,540 shares of ACADIA Pharmaceuticals stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $39.77, for a total transaction of $6,265,365.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) traded down 0.63% during trading on Thursday, hitting $39.22. The firm has a 50 day moving average price of $33.53 and a 200 day moving average price of $30.40. ACADIA Pharmaceuticals Inc. has a 1-year low of $17.02 and a 1-year high of $42.49. The stock’s market cap is $4.75 billion.

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this news story can be read at http://www.dailypolitical.com/2017/02/16/acadia-pharmaceuticals-inc-acad-evp-sells-6265365-80-in-stock.html.

A number of brokerages have issued reports on ACAD. Vetr cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating and set a $41.20 target price for the company. in a research report on Tuesday. Piper Jaffray Companies restated an “overweight” rating and set a $44.00 target price on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 7th. Ladenburg Thalmann Financial Services began coverage on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 2nd. They set a “buy” rating and a $48.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $49.00 target price on shares of ACADIA Pharmaceuticals in a research report on Tuesday, January 24th. Finally, Cowen and Company restated an “outperform” rating and set a $42.00 target price on shares of ACADIA Pharmaceuticals in a research report on Tuesday, January 24th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $41.25.

A number of institutional investors have recently made changes to their positions in the stock. Tocqueville Asset Management L.P. raised its position in shares of ACADIA Pharmaceuticals by 17.5% in the second quarter. Tocqueville Asset Management L.P. now owns 112,400 shares of the biopharmaceutical company’s stock worth $3,649,000 after buying an additional 16,750 shares in the last quarter. Kalos Management Inc. bought a new position in shares of ACADIA Pharmaceuticals during the second quarter worth about $230,000. EverPoint Asset Management LLC bought a new position in shares of ACADIA Pharmaceuticals during the second quarter worth about $16,230,000. Palo Alto Investors LLC raised its position in shares of ACADIA Pharmaceuticals by 196.4% in the second quarter. Palo Alto Investors LLC now owns 1,437,730 shares of the biopharmaceutical company’s stock worth $46,669,000 after buying an additional 952,630 shares in the last quarter. Finally, Fiera Capital Corp bought a new position in shares of ACADIA Pharmaceuticals during the second quarter worth about $6,280,000. Hedge funds and other institutional investors own 98.25% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).

5 Day Chart for NASDAQ:ACAD

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.